APOE and multiple sclerosis: As expected, given the clinical focus of IMI-funded NDD research, many of these assets are targeted at this stage of the drug development pipeline, including research cohorts (e.g., RADAR-CNS cohort of multiple sclerosis patients, EPAD longitudinal cohort study), patient samples and data (e.g., neuroimaging datasets from the AMYPAD studies, ADAPTED biosamples from people with different APOE genotypes) and tools for patient engagement, subject enrolment and clinical data analysis.